Kairos Pharma shares rise 10.07% premarket after winning 2025 Clinical Trials Arena R&D Award for ENV-105 with positive Phase 2 prostate cancer trial results.

Kairos Pharma (NYSE American: KAPA) surged 10.07% in premarket trading after being awarded the 2025 Clinical Trials Arena Research and Development Excellence Award for Advanced Prostate Cancer. The recognition highlights the company’s progress with ENV-105, a first-in-class CD105-targeting monoclonal antibody, which demonstrated 86% clinical benefit in a Phase 2 trial combining it with apalutamide for metastatic prostate cancer. The trial showed 50% of responders remained progression-free beyond one year, reinforcing the therapy’s potential to address drug resistance in advanced prostate cancer. The award underscores scientific validation of Kairos’s innovative approach, aligning with the stock’s bullish premarket reaction.